ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BSFA Bsf Enterprise Plc

2.375
0.00 (0.00%)
27 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bsf Enterprise Plc LSE:BSFA London Ordinary Share GB00BHNBDQ51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.375 2.25 2.50 2.375 2.375 2.375 11,240 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 13k -1.5M -0.0145 -1.63 2.45M

BSF Enterprise PLC Successful Cultivated Meat Test (8976A)

30/05/2023 7:00am

UK Regulatory


Bsf Enterprise (LSE:BSFA)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more Bsf Enterprise Charts.

TIDMBSFA

RNS Number : 8976A

BSF Enterprise PLC

30 May 2023

30 May 2023

BSF Enterprise PLC

("BSF" or the "Company")

Successful Cultivated Meat Test

BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that it has successfully produced a further two full-scale fillets of cultivated pork, as well as a cultivated pork strip, which were presented at a technical event on Friday 25 May 2023.

The cultivated pork fillets each measured 5 cm in diameter, 3 cm in height, and circa 60 g in weight, making them similar in size to traditional 2-ounce tenderloin steaks. This time, the Company had worked on increasing the thickness of the fillet in comparison to the fillet produced in January this year. In addition, the Company produced a cultivated pork strip, or 'noodle' measuring circa 30 cm in length and 1 cm in diameter. The development of the pork strip demonstrates the effectiveness of the Company's intellectual property in being applied to produce meat in the future as a consumer-ready, 'pre-sliced' form for cooking purposes.

The cultivated meat products were produced using 3DBT's patented, serum-free and animal-free cell booster City-Mix(TM) , which eliminates the requirement of conventional plant-based scaffolds, blends or fillers, as have been universally adopted by the industry to date to ensure structural integrity of cultivated meat products. 3DBT's products are therefore 100% structured meat, produced without any animals suffering in its production.

The latest iteration of 100% meat products underwent testing, with data collected and study participants invited to inspect the product in a raw and cooked state. Study participants were limited to those persons who had a direct working relationship or involvement with the Company. The cultivated meat fillets were then pan-fried and presented formally by a trained, independent chef, while the meat strip was first cut in two portions, and subsequently poached or pan-fried, in order to test an array of cooking methods. The chef's involvement was key to demonstrating that the cultivated meat could be handled and cooked in the same way as traditional meat, and the results were very positive.

The Company is pleased to confirm that the 100% cultivated meat products were very similar in appearance to conventional meat in their raw state, with fibres clearly visible. The results from cutting and cooking the fillets were also consistent with the previous results in terms of overall appearance, aroma and searing/crisping. The Study participants that tasted the cultivated meat provided very positive feedback in terms of its taste and texture.

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented: "We have gained a huge amount of valuable knowledge from testing our products with a trained chef and we were reassured to observe that our cultivated meat is able to be handled and cooked in the same way as traditional meat products. Further, data collected from the study participants indicated comparable meat qualities to traditional pork meat, which was very pleasing and highly validating of our work. This gives us further confidence as we continue our conversations with potential customers to licence out the technologies demonstrated as well as building on the agreements already secured."

Photographs of the cultivated meat products in raw and cooked states from the Test Event can be found below:

The raw fillets and pork strip.

The cooked pork fillets.

A portion of the cooked pork strip.

-Ends-

   For further enquiries, please visit   www.bsfenterprise.com   or contact: 
 
 
 
   BSF Enterprise PLC                          Via SEC Newgate 
                                               below 
 Che Connon - CEO & Executive 
  Director 
  Geoff Baker - Executive Director 
 
 
   Shard Capital (Broker) 
 Damon Heath                                 0203 971 7000 
  Isabella Pierre                             0207 1869 927 
 
 
   SEC Newgate (Financial Communications) 
 Bob Huxford                                 020 3757 6882 
  Elisabeth Cowell                            BSF@secnewgate.co.uk 
  George Esmond 
 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANSNALXDEFA

(END) Dow Jones Newswires

May 30, 2023 02:00 ET (06:00 GMT)

1 Year Bsf Enterprise Chart

1 Year Bsf Enterprise Chart

1 Month Bsf Enterprise Chart

1 Month Bsf Enterprise Chart

Your Recent History

Delayed Upgrade Clock